A Phase II Trial of G3139 (Genasense) Anti-Bcl-2 Antisense Oligonucleotide Plus Alpha-Interferon in Metastatic Renal Cancer.

Trial Profile

A Phase II Trial of G3139 (Genasense) Anti-Bcl-2 Antisense Oligonucleotide Plus Alpha-Interferon in Metastatic Renal Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2016

At a glance

  • Drugs Interferon alpha (Primary) ; Oblimersen (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Dec 2012 Actual initiation date changed from Feb 2003 to Aug 2003 as reported by ClinicalTrials.gov.
    • 23 Jun 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.
    • 03 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top